Anderson Silva

By FCF Staff

The MMA world has been rocked by yet another drug test scandal, as just days after their UFC 183 headliner, it’s been revealed that Nick Diaz and Anderson Silva have failed recent drug tests.

According to statements from the UFC, Silva allegedly tested positive for Drostanolone metabolites in a pre-fight drug test, and Diaz reportedly tested positive for marijuana metabolites following the January 31st event.

Here is the statement the promotion has released regarding Silva:

“On February 3, 2015, the UFC organization was notified by the Nevada State Athletic Commission that Anderson Silva tested positive for Drostanolone metabolites on his Jan. 9 out of competition drug test. UFC’s understanding is that further testing will be conducted by the Commission to confirm these preliminary results.

“Anderson Silva has been an amazing champion and a true ambassador of the sport of mixed martial arts and the UFC, in Brazil as well as around the world. UFC is disappointed to learn of these initial results.

“The UFC has a strict, consistent policy against the use of any illegal and/or performance enhancing drugs, stimulants or masking agents by its athletes.”

And here is the statement the UFC has made regarding Diaz:

“The UFC has been notified by the Nevada State Athletic Commission that Nick Diaz has tested positive for marijuana metabolites following his fight with Anderson Silva at UFC 183 on Jan. 31 in Las Vegas, Nev. The UFC has a strict, consistent policy against the use of any illegal and/or performance enhancing drugs, stimulants or masking agents by our athletes. As a result of his positive test, Diaz has been informed that he has violated the UFC Fighter Conduct Policy and Promotional Agreement with Zuffa, LLC. The UFC organization will fully respect the Commission’s final decision relating to Diaz at a disciplinary hearing set for February 17.

Silva worked his way to a unanimous decision win over Diaz at UFC 183, which was hosted by the MGM Grand Garden Arena in Las Vegas, Nevada.